NICE risks making itself a 'laughing stock' over guidance on metformin alternatives

Status
Not open for further replies.

Northerner

Admin (Retired)
Relationship to Diabetes
Type 1
Primary care experts are urging NICE to overhaul draft guidelines on type 2 diabetes, claiming recommendations to use the drug repaglinide are ‘bonkers’ and risk setting care back a decade, Pulse has learned.

The experts said the recommended treatment algorithm for glycaemic control was ‘nonsensical’, drawing particular attention to the promotion of the insulin secretagogue repaglinide – which primary care has ‘little understanding of’ because it is rarely prescribed.

The draft guidelines still recommend metformin as first-line initial therapy, but have demoted sulfonylureas from their position as a second-line or alternative option to metformin over concerns about their associated risks of hypoglycaemia.

http://www.pulsetoday.co.uk/clinica...ves-say-experts/20009139.article#.VNid1PmsWAg

(free registration required)
 
Status
Not open for further replies.
Back
Top